S&P 500 pharma stocks hold firm despite Trump’s drug pricing threat. Is Merck a put-selling opportunity amid headline noise?

US pharma giant Merck & Co (NYSE: MRK) today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...

American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. Immutep climbed 16% to $2.11 on ...

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single ...

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

On May 12th the president signed an executive order that seeks to force drugmakers to reduce their prices in America to align ...